Investor AB stock: Atlas Antibodies names interim CEO Henneveld

Investor AB's portfolio company Atlas Antibodies has appointed Morten Henneveld as interim chief executive, according to TipRanks. The appointment took effect on Sunday, November 1, 2026, after Dan Pitulia left the role by mutual agreement.

New leadership at Atlas Antibodies

Henneveld brings experience in healthcare and strategic change, according to the report. His appointment is intended to support Atlas Antibodies through its next phase of development. The announcement concerns an operating company in Investor AB's portfolio rather than a change to the investment company's own executive leadership.

For Investor AB shareholders, the development adds a portfolio-company leadership change to the holding company's broader active-ownership agenda. The immediate significance depends on how the new interim chief executive supports execution and strategic development at Atlas Antibodies; the announcement does not provide financial targets or a timetable for a permanent appointment.

Investor AB stock traded at 39.02 euros on Lang & Schwarz at 10:34 CET on Monday, November 2, 2026. Investors can follow the real-time quote of Investor AB stock.

Swedish equities are covered in the OMXS30 market environment.

Further developments can be followed through more news and analyses on Investor AB stock.